Canada · Delayed Price · Currency is CAD Genix Pharmaceuticals Statistics
Total Valuation
TSXV:GENX has a market cap or net worth of CAD 1.53 million. The enterprise value is 2.55 million.
| Market Cap | 1.53M |
| Enterprise Value | 2.55M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:GENX has 61.22 million shares outstanding.
| Current Share Class | 61.22M |
| Shares Outstanding | 61.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 32.37% |
| Owned by Institutions (%) | n/a |
| Float | 33.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22,508.87 |
| PB Ratio | -1.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -28.72 |
| EV / Sales | n/a |
| EV / EBITDA | 12.31 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | 4.94 |
| Debt / FCF | n/a |
| Interest Coverage | -2.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -163.17% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 23.79% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -22 |
| Employee Count | 4,000 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.54% in the last 52 weeks. The beta is 0.38, so TSXV:GENX's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -61.54% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 43.75 |
| Average Volume (20 Days) | 138,546 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, TSXV:GENX had revenue of CAD 68 and -88,759 in losses. Loss per share was -0.00.
| Revenue | 68 |
| Gross Profit | -182,994 |
| Operating Income | -339,244 |
| Pretax Income | -88,759 |
| Net Income | -88,759 |
| EBITDA | 207,044 |
| EBIT | -339,244 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 4,636 in cash and 1.02 million in debt, with a net cash position of -1.02 million or -0.02 per share.
| Cash & Cash Equivalents | 4,636 |
| Total Debt | 1.02M |
| Net Cash | -1.02M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -1.43M |
| Book Value Per Share | -0.02 |
| Working Capital | -1.43M |
Cash Flow
| Operating Cash Flow | -133,372 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -498,888.24% |
| Pretax Margin | -130,527.94% |
| Profit Margin | n/a |
| EBITDA Margin | 304,476.47% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:GENX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -5.80% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TSXV:GENX has an Altman Z-Score of -746.35. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -746.35 |
| Piotroski F-Score | n/a |